These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

972 related articles for article (PubMed ID: 9816214)

  • 1. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.
    Thor Straten P; Kirkin AF; Seremet T; Zeuthen J
    Int J Cancer; 1997 Mar; 70(5):582-6. PubMed ID: 9052759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
    Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
    Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
    Seliger B; Ritz U; Abele R; Bock M; Tampé R; Sutter G; Drexler I; Huber C; Ferrone S
    Cancer Res; 2001 Dec; 61(24):8647-50. PubMed ID: 11751378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.
    Maeurer MJ; Gollin SM; Martin D; Swaney W; Bryant J; Castelli C; Robbins P; Parmiani G; Storkus WJ; Lotze MT
    J Clin Invest; 1996 Oct; 98(7):1633-41. PubMed ID: 8833913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity.
    Tao J; Li Y; Liu YQ; Wang L; Yang J; Dong J; Wu Y; Shen GX; Tu YT
    J Invest Dermatol; 2008 Aug; 128(8):1991-6. PubMed ID: 18385764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
    Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
    Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
    Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations.
    Geertsen R; Böni R; Blasczyk R; Romero P; Betts D; Rimoldi D; Hong X; Laine E; Willers J; Dummer R
    Int J Cancer; 2002 May; 99(1):82-7. PubMed ID: 11948496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
    Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.